Sugentech Inc (253840) - Total Liabilities
Based on the latest financial reports, Sugentech Inc (253840) has total liabilities worth ₩21.45 Billion KRW (≈ $14.53 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Sugentech Inc (253840) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Sugentech Inc - Total Liabilities Trend (2017–2025)
This chart illustrates how Sugentech Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Sugentech Inc asset portfolio.
Sugentech Inc Competitors by Total Liabilities
The table below lists competitors of Sugentech Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Simula Technology
TWO:3511
|
Taiwan | NT$764.40 Million |
|
Changhae Ethanol Co. Ltd
KQ:004650
|
Korea | ₩52.91 Billion |
|
Unigold Inc.
V:UGD
|
Canada | CA$424.21K |
|
Ashmore Asset Management Indonesia
JK:AMOR
|
Indonesia | Rp88.92 Billion |
|
Francotyp-Postalia Holding AG
F:FPH
|
Germany | €113.20 Million |
|
East Asia Holdings Investment Limited
KQ:900110
|
Korea | ₩18.10 Billion |
|
Clene Inc.
NASDAQ:CLNN
|
USA | $47.82 Million |
|
Tevogen Bio Holdings Inc.
NASDAQ:TVGN
|
USA | $13.62 Million |
Liability Composition Analysis (2017–2025)
This chart breaks down Sugentech Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Sugentech Inc net asset quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 10.82 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.30 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.23 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Sugentech Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Sugentech Inc (2017–2025)
The table below shows the annual total liabilities of Sugentech Inc from 2017 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | ₩21.67 Billion ≈ $14.68 Million |
+106.09% |
| 2024-12-31 | ₩10.51 Billion ≈ $7.13 Million |
-49.28% |
| 2023-12-31 | ₩20.73 Billion ≈ $14.05 Million |
-36.64% |
| 2022-12-31 | ₩32.72 Billion ≈ $22.17 Million |
-40.35% |
| 2021-12-31 | ₩54.85 Billion ≈ $37.17 Million |
+486.64% |
| 2020-12-31 | ₩9.35 Billion ≈ $6.34 Million |
-55.71% |
| 2019-12-31 | ₩21.11 Billion ≈ $14.31 Million |
+136.82% |
| 2018-12-31 | ₩8.92 Billion ≈ $6.04 Million |
-82.55% |
| 2017-12-31 | ₩51.09 Billion ≈ $34.62 Million |
-- |
About Sugentech Inc
Sugentech Inc. develops and sells in-vitro diagnostic systems and products based on biotechnology, information technology, and nanotechnology in South Korea and internationally. The company offers lab tests, including systems and test items; and COVID-19 tests. It also provides point of care testing analyzers and test items for testing of influenza A/B, antibody test, COVID-19 and flu, SARS-CoV-2… Read more